CG Oncology (CGON) Operating Expenses (2023 - 2026)
CG Oncology's (CGON) quarterly Operating Expenses came in at $67.5 million in Q1 2026, up 59.67% YoY from $42.3 million in Q1 2025, and up 32.24% on a QoQ basis from $51.0 million in Q4 2025.
CG Oncology (CGON) Operating Expenses (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Operating Expenses data on file, last reported at $67.5 million in Q1 2026.
- Quarterly Operating Expenses rose 59.67% year-over-year to $67.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.0 million (up 62.91% YoY) and the FY2025 annual result came in at $194.8 million, up 68.23% from the prior year.
- Operating Expenses advanced to $67.5 million in Q1 2026, from $51.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $67.5 million in Q1 2026 to a low of $9.9 million in Q1 2023.
- A 4-year average of $33.4 million and a median of $28.3 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 131.95% — and 2025, when it soared 32.51%.
- Tracing CGON's Operating Expenses over 4 years: stood at $19.4 million in 2023, then jumped by 98.93% to $38.5 million in 2024, then surged by 32.51% to $51.0 million in 2025, then jumped by 32.24% to $67.5 million in 2026.
- The last three Operating Expenses figures came in at $67.5 million (Q1 2026), $51.0 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 87.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.56 Mn |
| Mar 31, 2026 | 67.47 Mn |
| Dec 31, 2025 | 51.02 Mn |
| Sep 30, 2025 | 52.80 Mn |
| Jun 30, 2025 | 48.74 Mn |
| Mar 31, 2025 | 42.26 Mn |
| Dec 31, 2024 | 38.51 Mn |
| Sep 30, 2024 | 28.34 Mn |
| Jun 30, 2024 | 25.96 Mn |
| Mar 31, 2024 | 23.00 Mn |
| Dec 31, 2023 | 19.36 Mn |
| Sep 30, 2023 | 14.05 Mn |
| Jun 30, 2023 | 12.33 Mn |
| Mar 31, 2023 | 9.92 Mn |